To further explore the utility of such combinations, phase 1 or 2 studies pairing ipilimumab in regimens with sipuleucel-T, off-the-shelf prostate cancer vaccines, and/or adjuvants such as granulocyte macrophage colony-stimulating growth factor (GM-CSF) are complete or underway 31,32. Here, CSF2 is linked to prostate cancer.